TIME FOR LIFE

R-MAB

Rituximab

Concentrate for solution for infusion

  • Antineoplastic agents. Monoclonal antibodies.
  • Chimeric human-murine monoclonal antibody to the lymphocyte’s transmembrane antigen CD20, located on pre-B and mature B lymphocytes.
  • R-MAB is approved to first-line treatment of B-cell non-Hodgkin’s lymphomas and chronic lymphocytic leukemia, rheumatoid arthritis and granulomatosis with polyangiitis (Wegener’s granulomatosis) and microscopic polyangiitis.
  • R-МAB is the first biosimilar of Mabtera®/Rituxan® in Belarus with the identity of the molecular structure and mechanisms of action, efficacy and safety profile proven in comparative clinical studies.